Lorbrena (lorlatinib) — Medica
Non-Small Cell Lung Cancer – ROS1 Rearrangement-Positive
Initial criteria
- Patient is age ≥ 18 years
- Patient has advanced or metastatic disease
- Patient has ROS1 rearrangement-positive disease
- Patient has tried at least one of the following: Xalkori (crizotinib), Zykadia (ceritinib), or Rozlytrek (entrectinib)
Approval duration
1 year